Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by cacfacmaon Feb 23, 2024 8:20am
212 Views
Post# 35895138

yesterday's call

yesterday's callIn my opinion, Baxter does not want Spectral price to pop prior to its IPO of Vantive and is calling the shots.  Why would we expect otherwise?  Baxter is the big whale, Spectral is the little fish. 

I do not believe there is any statistical hit associated with releasing crude mortality results at 90 patients.   Clearly, if this was the case, Spectral would not have gone on record a year ago that they would release these interim results.  

We should all be reviewing analyst reports from Baxter to pick up on any reference to upcoming Vantive IPO and related details on PMX/EAA.


<< Previous
Bullboard Posts
Next >>